The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron under Ongoing Collaboration
Sep 04, 2024•almost 2 years ago
Contract Type
partnership
San FranciscoBiotechnology
Description
Sonoma Biotherapeutics, Inc. has received a $45 million milestone payment from Regeneron Pharmaceuticals, Inc. under their ongoing collaboration to discover, develop, and commercialize engineered Treg therapies for autoimmune diseases. The payment marks a significant milestone in their evolution as a company and their collaboration with Regeneron.
Company Information
Company
Sonoma Biotherapeutics
Location
San Francisco, California, United States
About
Sonoma Biotherapeutics is a South San Francisco and Seattle-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. Sonoma Bio has initiated two Phase 1 studies to evaluate the safety and proof-of-mechanism of the company’s lead Treg cell therapy candidate, SBT-77-7101, in patients with rheumatoid arthritis and hidradenitis suppurativa. The company has a partnership with Regeneron to discover, develop and commercialize novel regulatory T cell therapies.
San FranciscoBiotechnology